Iovance Biotherapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.

CEO

Frederick G. Vogt

CEOFrederick G. Vogt

Employees

838

Employees838

Headquarters

San Carlos, California

HeadquartersSan Carlos, California

Founded

2007

Founded2007

Employees

838

Employees838

IOVA Key Statistics

Market cap

776.18M

Market cap776.18M

Price-Earnings ratio

-1.85

Price-Earnings ratio-1.85

Dividend yield

—

Dividend yield—

Average volume

13.01M

Average volume13.01M

High today

$2.30

High today$2.30

Low today

$2.10

Low today$2.10

Open price

$2.26

Open price$2.26

Volume

13.69M

Volume13.69M

52 Week high

$12.51

52 Week high$12.51

52 Week low

$1.64

52 Week low$1.64

IOVA News

Simply Wall St 5d

A Look at Iovance Biotherapeutics’s Valuation Following FDA Approval of Amtagvi for Solid Tumors

Iovance Biotherapeutics (IOVA) made headlines after securing the first FDA approval for an immune cell therapy targeting solid tumors with its drug, Amtagvi. On...

The Motley Fool 5d

Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health

Is there a glimmer of hope for either of these underperforming healthcare companies? Here's a great way to earn strong market returns over the long term: Ident...

Analyst ratings

58%

of 12 ratings

Buy

58.3%

Hold

33.3%

Sell

8.3%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Recursion Pharmaceuticals